目的 研究苁蓉益肾颗粒联合盐酸普拉克索片治疗帕金森病的临床疗效。方法 选取2016年5月-2019年5月在天津市东丽区东丽医院治疗的100例帕金森病患者为研究对象，将所有患者随机分为对照组和治疗组，每组各50例。对照组患者口服盐酸普拉克索片，第1周起始剂量为0.375 mg/d，第2周0.75 mg/d，每周加量1次，每次日剂量增加0.75 mg，每日最大剂量为4.5 mg，3次/d；治疗组在对照组治疗的基础上口服苁蓉益肾颗粒，1袋/次，2次/d。两组患者持续治疗3个月。观察两组的临床疗效，比较两组的简易智力状态检查量表（MMSE）评分、统一帕金森病评分量表（UPDRS）评分、血清胱抑素C（Cys-C）和丙二醛（MDA）水平。结果 治疗后，对照组和治疗组的总有效率分别为74.00%、94.00%，两组比较差异有统计学意义（P<0.05）。治疗后，两组患者MMSE评分显著升高，UPDRS评分显著降低，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组MMSE评分和UPDRS评分均明显优于对照组，两组比较差异有统计学意义（P<0.05）。治疗后，两组患者血清Cys-C和MDA水平均显著降低，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组血清Cys-C和MDA水平均明显低于对照组，两组比较差异有统计学意义（P<0.05）。结论 苁蓉益肾颗粒联合盐酸普拉克索片治疗帕金森病具有较好的疗效，可改善患者MMSE评分和UPDRS评分，降低血清Cys-C和MDA水平，具有一定的临床推广应用价值。

Objective To study the effect of Congrong Yishen Granules combined with Pramipexole Dihydrochloride Tablets in treatment of Parkinson's disease. Methods Patients (100 cases) with Parkinson's disease in Tianjin Dongli Hospital from May 2016 to May 2019 were randomly divided into control and treatment groups, and each group had 50 cases. Patients in the control group were po administered with Pramipexole Dihydrochloride Tablets, the initial dose was 0.375 mg/d in the first week, the dose was increased to 0.75 mg/d in the second week, after that, the dose increased 1 times a week, increased 0.75 mg every time, and the maximum daily dose was 4.5 mg, three times daily. Patients in the treatment group were po administered with Congrong Yishen Granules on the basis of the control group, 1 bag/time, twice daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacies were evaluated, and MMSE score, UPDRS score, the levels of Cys-C and MDA in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 74.00% and 94.00%, respectively, and there was difference between two groups (P<0.05). After treatment, the MMSE score in two groups were significantly increased, but the UPDRS score in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the scores in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of Cys-C and MDA in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the levels of Cys-C and MDA in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Congrong Yishen Granules combined with Pramipexole Dihydrochloride Tablets has clinical curative effect in treatment of Parkinson's disease, can improve MMSE score and UPDRS score, and reduce the levels of Cys-C and MDA, which has a certain clinical application value.

R971